SCHEMBL6894723

SCHEMBL6894723

CCc1cc(O)c2c3c(C(=O)OC)cccc3n(Cc3ccccc3C)c2c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.45
KDM4E B2RXH2 5/20 0.45
ALDH1A1 P00352 5/20 0.45
MEN1 O00255 3/20 0.45
KMT2A Q03164 3/20 0.45
NPSR1 Q6W5P4 3/20 0.45
GAA P10253 1/20 0.45
LMNA P02545 5/20 0.41
HTT P42858 3/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
HIF1A Q16665 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
TSHR P16473 2/20 0.41
TDP1 Q9NUW8 2/20 0.41
HSD17B10 Q99714 2/20 0.41
RECQL P46063 1/20 0.41
PLA2G2A P14555 1/20 0.39
THRB P10828 1/20 0.39
TP53 P04637 2/20 0.38
SHBG P04278 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6897067 0.90 CNR1 (0.41) MAPTKDM4EALDH1A1MEN1KMT2A
SCHEMBL6897168 0.90 PLA2G1B (0.44) MAPTKDM4EALDH1A1MEN1KMT2A
SCHEMBL6780594 0.90 MEN1 (0.43) MAPTKDM4EALDH1A1MEN1KMT2A
SCHEMBL6892544 0.89 MAPT (0.44) MAPTKDM4EALDH1A1MEN1KMT2A
SCHEMBL6890571 0.89 MAPT (0.45) MAPTKDM4EALDH1A1MEN1KMT2A
SCHEMBL6892764 0.89 LMNA (0.44) MAPTKDM4EALDH1A1MEN1KMT2A
SCHEMBL6892130 0.89 HSP90AA1 (0.38) MAPTKDM4EALDH1A1MEN1KMT2A
SCHEMBL6894814 0.88 MAPT (0.44) MAPTKDM4EALDH1A1MEN1KMT2A
SCHEMBL6689180 0.88 LMNA (0.47) MAPTKDM4EALDH1A1MEN1KMT2A
SCHEMBL6896536 0.88 MAPK8 (0.47) MAPTKDM4EALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6713645-B1 INHIBITING SPLA2 MEDIATED RELEASE OF FATTY ACIDS FOR TREATMENT OF CONDITIONS SUCH AS SEPTIC SHOCK ELI LILLY AND COMPANY 2004-03-30 US disclosed
US-6177440-B1 THERAPY FOR SEPSIS SHOCK; PHOSPHOLIPASE INHBITOR ELI LILLY AND COMPANY 2001-01-23 US disclosed
EP-0952149-A2 Substituted carbazoles, process for their preparation and their use as sPLA2 inhibitiors ELI LILLY AND COMPANY (US) 1999-10-27 EP disclosed